P07.02 Real World data of Advanced Non-Small Cell Lung Cancer Patients EGFR Mutated from a Peruvian Cohort

Tyrosine kinase inhibitors anti-EGFR are the standard of care for NSCLC patients with sensitive EGFR mutations, however, the knowledge on the real benefit of these therapies in the real-world setting remains unclear. The aim of this study is to evaluate the characteristics and outcomes of EGFR mutated NSCLC patients treated in a real-world Latin American setting. Retrospective analysis of advanced NSCLC patients EGFR mutated diagnosed at Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima-Peru from 2013 to 2020. Main clinical analysis, including ORR, PFS and OS, was performed only in patients who received anti-EGFR TKI (Erlotinib) at the institution. Data were collected from medical records. During the study period, we analyzed the EGFR mutational status of 448 cases using tissue PCR or liquid biopsy in cases of insufficient material. Pathological EGFR mutations was found in 47% patients (n=211). Among these, the distribution of mutations was as follows: 61% exon 19 deletion, 25% L858R mutation, 12.6% EGFR uncommon mutations/associations, and 1.4% de-novo T790M mutation. Median age at diagnosis was 60 years (range 22-89y) and most patient were females (65.9%). Out of EGFR mutated patients, 129 (61.1%) received anti-EGFR TKI as a part of treatment at INEN, of them, 20.2% had smoking history and 24.8% biomass exposition as a main risk factor. About clinical presentation, 96 patients (74.4%) had status performance 1 (ECOG) and 37 (28.7%) presented brain metastases at diagnosis. Concerning treatment, 64.3% of patients (n=83) received TKI as first line and 35.7% as second or later line of treatment. The ORR was 86.8%. Median PFS was 14.13 months and median OS was 29.73 months. No differences in PFS and OS were found according to line of treatment (first vs second or later, p=0.69 and p=0.29 respectively) or type of mutation (exon 19 deletion vs L858R mutation vs uncommon mutations/associations, p=0.84 and p=0.50). Out of the 76 patients who progressed, half of them had T790M mutation assessment, finding 27.6% positive cases (21 patients). The proportion of EGFR mutated NSCLC in this cohort is higher than the reported in other countries outside Latin America or Asia. Our patients achieve high response rates and prolonged survival with no differences between the line of treatment or type of mutation. Results of this analysis confirm the benefit of use target therapies in the real-world setting.